The state of HER-2 status

Annals of Oncology

Volumn 18, Issue 5, 2007, Pages 813-815

  Di Leo, A ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTIESTROGEN; AROMATASE INHIBITOR; CYTOTOXIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; LAPATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; RNA; SOMATOMEDIN C; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BREAST CANCER; CANCER RECURRENCE; CANCER RELAPSE; CANCER SIZE; CANCER SURVIVAL; CHROMOSOME 17; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG INDICATION; DRUG SENSITIVITY; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MICROARRAY ANALYSIS; MONOTHERAPY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SIGNAL TRANSDUCTION;

EID: 34447251786     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm179     Document Type: Editorial

References (34)

1. Bergqvist J, Ohd J, Smeds J et al. Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Ann Oncol 2007; 18: 845-850.
2. Slamon DJ, Leyland-Jones B, Shak S et al, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
4. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
5. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
6. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005; 94: S5 (Abstr 1).
7. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER-2 positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
8. Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95: 353-361.
9. Dowsett M, Allred DC. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 2006; 100: S21 (Abstr 48).
10. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive. estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
11. Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23: 5108-5116.
12. Colazza M, Azambuja E, Cardoso F et al. Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now?. Ann Oncol 2005; 16: 1723-1739.
13. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-6 in early breast cancer. J Clin Oncol 2005; 23: 7212-7220.
14. Ross JS, Fletcher A, Linette GP et al. The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist 2003; 8: 307-325.
15. Schroeter CA, De Potter CR, Rathsmann K et al. c-erbB-2 positive breast tumours behave more agqressivuly in the first years after diagnosis. Br J Cancer 1992; 66: 728-734.
16. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J clin Oncel 1996; 14: 2738-2746.
17. Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295: 1658-1667.
18. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 2005; 16: 1569-1583.
19. Paik S. Iang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734.
20. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334-2356.
21. Di Leo A. Isola J. Iopoisonnerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: Are we at the end of the beginning?. Clin Breast Cancer 2003; 4: 179-186.
22. Di Leo A, Larsimont D, Gancberg D et al. HER-2 and topo-isomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001; 12: 1081-1089.
23. Durbecq V, Paesmans M, Cardoso F et al. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Their 2004; 3: 1207-1214.
24. O'Malley FP, Chia S, Tu D et al. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA. 5). Breast Cancer Res Treat 2006; 100: S18 (Abstr 38).
25. Durbecq V, Desmedt C, Paesmans M et al. Correlation between topoisomerase II alpha gene amplification and protein expression in HLR-2 amplified breast cancer. Int J Oncol 2004; 25: 1473-1479.
26. Mueller RE. Parkes RK, Andrulis I et al. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004; 39: 288-297.
27. Callagy G, Pharoah P, Chin SF et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 2005; 205: 388-396.
28. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
29. Paik S, Bryant J, Tan-Chiu E et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002; 94: 852-854.
30. Perez EA, Suman VJ, Davidson NE et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006; 24: 3032-3038.
31. Persens DL. Iubbs RR, Cooley LD et al. HER-2 fluorescense in situ hybridization: Results from the survey program of the College of American Pathologists. Arch Pathol Lab Med 2006; 130: 325-331.
32. Roche PC, Suman VJ, Jenkins RB et al. Concordance between local and central laboratory HER2testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002; 94: 855-857.
33. Nahta R, Esteva FJ. HFR2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8: 215.
34. Ma Y, Lespagnard L, Durbecq V et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: Effect on daily practice. Clin Cancer Res 2005; 11: 4393-4399.